ONGAVIA is a prescription medication designed for the treatment of adults with type 2 diabetes mellitus to improve glycemic control. It is part of a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by increasing insulin release in response to high blood sugar levels, decreasing the amount of sugar made by the liver, and slowing the absorption of food in the stomach. ONGAVIA is administered through subcutaneous injection and is often used in combination with diet and exercise to achieve better blood sugar management in patients. It is important for patients to follow their healthcare provider's instructions regarding dosage and administration to effectively manage their condition and minimize potential side effects.